Applied Filters
Event preview: The election, Brexit, and the UPC
Ahead of the IQPC - Life Science IP conference in London, Kevin Mooney, chairman of the rules and procedure committee at the UPC, answers pressing questions on the IP landscape post-Brexit and the future of the Europe-wide patents court project.
Event preview: BIO-Europe returns to Hamburg
The special 25th anniversary BIO-Europe 2019 global life science partnering event will be held November 11–13, 2019, in Hamburg, Germany.
Event preview: Life Sciences IP Due Diligence summit
The Annual Summit on Life Sciences IP Due Diligence to be held on November 14 and 15 in Boston, MA, is a one-of-a-kind, interactive forum where diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis for incumbent portfolios and those of potential targets.
Conference preview: LSX World Congress USA
LSX World Congress USA brings life sciences investment and partnering to Boston.
Brexit: The waiting game
As lawyers and industry prepare for a possible no-deal Brexit, the uncertainty surrounding its impact is palpable, as LSIPR’s Saman Javed discovers.
M&A: Year of the megadeal
LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity.
Pharma: A Mexican tradeoff
While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.
Genetic research: DNA payday
A tie-up between four leading pharmaceutical companies, the UK government and a health charity has created the world’s largest genetic research project. LSIPR’s Rory O’Neill looks at a new frontier for life sciences.
Conference preview: BioPharm America 2019
Held during Boston’s week-long Biotech festival, BioPharm America promises its 4,500 delegates excellent knowledge, networking, and deal opportunities, says Guadalupe Rodriguez of EBD Group.
Shire Pharmaceuticals: A culture of excellence
LSIPR provides a look behind the scenes of Shire Pharmaceuticals, the Irish company valued at £46 billion by its acquirer Takeda.
